BIOMAT Database Logo BIOMAT Database Logo

Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. 1988

M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Patas monkeys (Eryphrocebus patas) were immunized intradermally with two vaccinia virus recombinants that individually express the hemagglutinin-neuraminidase glycoprotein or the fusion glycoprotein of human parainfluenza virus type 3 (PIV3). These immunizations induced a high titer of PIV3 serum-neutralizing antibodies. At 1 month after immunization, monkeys were challenged intratracheally with PIV3. Subsequent virus replication was reduced in these monkeys by 3.2 log10 and 1.9 log10 (mean peak virus titers) in the upper and lower respiratory tracts, respectively, compared with control animals. The average duration of virus shedding was also reduced from 9.0 to 3.4 days in the upper respiratory tract and from 5.3 to 1.2 days in the lower respiratory tract. These findings demonstrate that a single intradermal dose of live recombinant vaccinia viruses can significantly restrict the replication of a virus which primarily infects the epithelial cells of the respiratory tract.

UI MeSH Term Description Entries
D010224 Parainfluenza Virus 3, Human A species of RESPIROVIRUS frequently isolated from small children with pharyngitis, bronchitis, and pneumonia. Hemadsorption Virus 1,Human parainfluenza virus 3,Para-Influenza Virus Type 3,Parainfluenza Virus Type 3,Para Influenza Virus Type 3
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D004901 Erythrocebus patas A species of the genus ERYTHROCEBUS, subfamily CERCOPITHECINAE, family CERCOPITHECIDAE. It inhabits the flat open arid country of Africa. It is also known as the patas monkey or the red monkey. Monkey, Patas,Monkey, Red,Patas Monkey,Red Monkey,Monkeys, Patas,Monkeys, Red,Patas Monkeys,Red Monkeys
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
April 1990, Vaccine,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.
April 1983, Nature,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
October 2001, The Journal of infectious diseases,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
August 2000, Journal of virology,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3.
April 1988, The Journal of infectious diseases,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.
August 2003, The Journal of general virology,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein.
August 1991, Virology,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
August 1998, Vaccine,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Protective antibodies against human parainfluenza virus type 3 infection.
January 2021, mAbs,
M K Spriggs, and P L Collins, and E Tierney, and W T London, and B R Murphy
Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.
December 2000, Journal of virology,
Copied contents to your clipboard!